Pharmaceutical formulation

Details Pharmaceutical formulation Pharmaceutical formulation

2007-09-04

2010-06-01

Kosar, Andrew D (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S324000, C514S023000, C424S001730

Reexamination Certificate

active

07727958

ABSTRACT:
A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant.

REFERENCES:
patent: 4847240 (1989-07-01), Ryser et al.
patent: 5652122 (1997-07-01), Frankel et al.
patent: 5670617 (1997-09-01), Frankel et al.
patent: 5674980 (1997-10-01), Frankel et al.
patent: 5747641 (1998-05-01), Frankel et al.
patent: 5783405 (1998-07-01), Mochly-Rosen et al.
patent: 5804604 (1998-09-01), Frankel et al.
patent: 5888762 (1999-03-01), Joliot et al.
patent: 6165977 (2000-12-01), Mochly-Rosen
patent: 6316003 (2001-11-01), Frankel et al.
patent: 6593292 (2003-07-01), Rothbard et al.
patent: 6855693 (2005-02-01), Mochly-Rosen et al.
patent: 6933275 (2005-08-01), Mochly-Rosen et al.
patent: 7265092 (2007-09-01), Li
patent: 2002/0057413 (2002-05-01), Sumida et al.
patent: 2002/0150984 (2002-10-01), Mochly-Rosen et al.
patent: 2002/0168354 (2002-11-01), Mochly-Rosen
patent: 2003/0104622 (2003-06-01), Robbins et al.
patent: 2003/0199677 (2003-10-01), Avrameas et al.
patent: 2003/0206900 (2003-11-01), Ternynck et al.
patent: 2003/0223981 (2003-12-01), Mochly-Rosen et al.
patent: 2004/0009922 (2004-01-01), Mochly-Rosen
patent: 2004/0204364 (2004-10-01), Mochly-Rosen et al.
Fuchs, S., D. Bartfeld, et al. (1980). “Immune regulation of experimental myasthenia.”J Neurol Neurosurg Psychiatry43(7): 634-43.
Tarrab-Hazdai, R., Y. Schmidt-Sole, et al. (1980). “Modification of acetylcholine receptor: chemical and immunological characterization of polyalanyl acetylcholine receptor.”FEBS Lett118(1): 35-8.
Fuchs, S., D. Bartfeld, et al. (1981). “Molecular aspects of experimental autoimmune myasthenia gravis.”Prog Clin Biol Res63: 405-17.
Fuchs, S., D. Bartfeld, et al. (1981). “Acetylcholine receptor: molecular dissection and monoclonal antibodies in the study of experimental myasthenia.”Ann N Y Acad Sci377: 110-24.
Mochly-Rosen, D. and S. Fuchs (1981). “Monoclonal anti-acetylcholine-receptor antibodies directed against the cholinergic binding site.”Biochemistry20(20): 5920-4.
Goldberg, G., D. Mochly-Rosen, et al. (1983). “Monoclonal antibodies modify acetylcholine-induced ionic channel properties in cultured chick myoballs.”J Membr Biol76(2): 123-8.
Pizzighella, S., A. S. Gordon, et al. (1983). “An anti-acetylcholine receptor monoclonal antibody cross-reacts with phosvitin.”FEBS Lett159(1-2): 246-50.
Souroujon, M. C., D. Mochly-Rosen, et al. (1983). “Interaction of monoclonal antibodies to Torpedo acetylcholine receptor with the receptor of skeletal muscle.”Muscle Nerve6(4): 303-11.
Souroujon, M. C., S. Pizzighella, et al. (1985). “Antigenic specificity of acetylcholine receptor in developing muscle. Studies with monoclonal antibodies.”J Neuroimmunol8(2-3): 159-66.
Bollag, G. E., R. A. Roth, et al. (1986). “Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity.”Proc Natl Acad Sci U S A83(16): 5822-4.
Baudier, J., D. Mochly-Rosen, et al. (1987). “Comparison of S100b protein with calmodulin: interactions with melittin and microtubule-associated tau proteins and inhibition of phosphorylation of tau proteins by protein kinase C.”Biochemistry26(10): 2886-93.
Krauss, S. W., D. Mochly-Rosen, et al. (1987). “Exposure of HeLa DNA polymerase alpha to protein kinase C affects its catalytic properties.”J Biol Chem262(8): 3432-5.
Mochly-Rosen, D., A. I. Basbaum, et al. (1987). “Distinct cellular and regional localization of immunoreactive protein kinase C in rat brain.”Proc Natl Acad Sci U S A84(13): 4660-4.
Mochly-Rosen, D. and D. E. Koshland, Jr. (1987). “Domain structure and phosphorylation of protein kinase C.”J Biol Chem262(5): 2291-7.
Mochly-Rosen, D., F. H. Chang, et al. (1988). “Chronic ethanol causes heterologous desensitization of receptors by reducing alpha s messenger RNA.”Nature333(6176): 848-50.
Mochly-Rosen, D. and D. E. Koshland, Jr. (1988). “A general procedure for screening inhibitory antibodies: application for identifying anti-protein kinase C antibodies.”Anal Biochem170(1): 31-7.
Gordon, A. S., L. Nagy, et al. (1990). “Chronic ethanol-induced heterologous desensitization is mediated by changes in adenosine transport.”Biochem Soc Symp56: 117-36.
Mochly-Rosen, D. and A. S. Gordon (1990). “GTP-binding proteins are restricted to signal transduction sites.”Biochem Biophys Res Commun173(1): 388-95.
Diamond, I., L. Nagy, et al. (1991). “The role of adenosine and adenosine transport in ethanol-induced cellular tolerance and dependence. Possible biologic and genetic markers of alcoholism.”Ann N Y Acad Sci625: 473-87.
Simon, A. J., Y. Milner, et al. (1991). “The identification and purification of a mammalian-like protein kinase C in the yeastSaccharomyces cerevisiae.” Proc Biol Sci243(1307): 165-71.
Smith, B. L. and D. Mochly-Rosen (1992). “Inhibition of protein kinase C function by injection of intracellular receptors for the enzyme.”Biochem Biophys Res Commun188(3): 1235-40.
Simon, A. J., S. P. Saville, et al. (1993). “Characterization of PKC2, a gene encoding a second protein kinase C isotype ofSaccharomyces cerevisiae.” Curr Biol3(12): 813-21.
Disatnik, M. H., G. Buraggi, et al. (1994). “Localization of protein kinase C isozymes in cardiac myocytes.”Exp Cell Res210(2): 287-97.
Garcia-Navarro, S., Y. Marantz, et al. (1994). “Developmental expression of protein kinase C subspecies in rat brain-pituitary axis.”Mol Cell Endocrinol103(1-2): 133-8.
Ron, D., C. H. Chen, et al. (1994). “Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins.”Proc Natl Acad Sci U S A91(3): 839-43.
Brzoska, P. M., H. Chen, et al. (1995). “The product of the ataxia-telangiectasia group D complementing gene, ATDC, interacts with a protein kinase C substrate and inhibitor.”Proc Natl Acad Sci U S A92(17): 7824-8.
Disatnik, M. H., S. N. Jones, et al. (1995). “Stimulus-dependent subcellular localization of activated protein kinase C; a study with acidic fibroblast growth factor and transforming growth factor-beta 1 in cardiac myocytes.”J Mol Cell Cardiol27(11): 2473-81.
Johnson, J. A., S. Adak, et al. (1995). “Prolonged phorbol ester treatment down-regulates protein kinase C isozymes and increases contraction rate in neonatal cardiac myocytes.”Life Sci57(11): 1027-38.
Mochly-Rosen, D. (1995). “Localization of protein kinases by anchoring proteins: a theme in signal transduction.”Science268(5208): 247-51.
Ron, D., J. Luo, et al. (1995). “C2 region-derived peptides inhibit translocation and function of beta protein kinase C in vivo.”J Biol Chem270(41): 24180-7.
Ron, D. and D. Mochly-Rosen (1995). “An autoregulatory region in protein kinase C: the pseudoanchoring site.”Proc Natl Acad Sci U S A92(2): 492-6.
Johnson, J. A., M. O. Gray, et al. (1996). “An improved permeabilization protocol for the introduction of peptides into cardiac myocytes. Application to protein kinase C research.”Circ Res79(6): 1086-99.
Smith, B. L., B. W. Krushelnycky, et al. (1996). “The HIV nef protein associates with protein kinase C theta.”J Biol Chem271(28): 16753-7.
Zhou, L. Y., M. Disatnik, et al. (1996). “Differential activation of protein kinase C isozymes by phorbol ester and collagen in human skin microvascular endothelial cells.”J Invest Dermatol107(2): 248-52.
Csukai, M., C. H. Chen, et al. (1997). “The coatomer protein beta'-COP, a selective binding protein (RACK) for protein kinase Cepsilon.”J Biol Chem272(46): 29200-6.
Gray, M. O., J. S. Karliner, et al. (1997). “A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death.

Affiliated with

Also associated with

Rating

Pharmaceutical formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4239595